Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group (LFST) reported a Form 4/A by its Chief People Officer correcting a prior filing. The amendment updates the number of shares withheld for taxes on PSUs vested on March 7, 2025 from 3,725 to 7,450, and updates holdings to 376,430 shares following the reported transactions.
Activity included: a grant of 76,142 RSUs on March 6, 2025; tax withholdings of 6,455 shares at $7.88 on March 6, 2025; PSU vestings of 27,740 and 32,052 on March 7, 2025; and additional tax withholdings of 7,450 shares at $7.59 and 8,606 shares at $7.59. The filing notes these withholdings reduce shares delivered and are not open‑market sales.
LifeStance Health Group (LFST) reported higher Q3 2025 results. Total revenue reached $363.8 million, up from $312.7 million a year ago. Income from operations was $7.4 million versus $0.05 million, and net income was $1.1 million compared with a prior-year net loss. For the first nine months, revenue was $1.04 billion and net loss narrowed to $2.0 million.
Cash and cash equivalents were $203.9 million, and net cash provided by operating activities rose to $88.6 million for the nine-month period. Long-term debt, net, was $269.4 million. Q3 Center Margin was $116.6 million and Adjusted EBITDA was $40.2 million. The company remained in compliance with debt covenants.
Commercial payors represented 90% of Q3 revenue, with government at 5% and self-pay at 4%. The interest rate swap matured on September 30, 2025. As of October 29, 2025, 389,000,281 common shares were outstanding.
LifeStance Health Group, Inc. (LFST) furnished quarterly materials. The company announced it furnished a press release covering results for the third quarter ended September 30, 2025 under Item 2.02, and a supplemental investor slide presentation under Item 7.01.
Both items are furnished, not filed, and are not incorporated by reference into other SEC filings unless expressly referenced. Exhibits include 99.1 (press release dated November 6, 2025) and 99.2 (supplemental slides), along with the Inline XBRL cover page file.
LifeStance Health Group (LFST) reported an insider equity award. A director acquired 74,766 shares of common stock on 08/20/2025 at $0.00, as shown on a Form 4.
The filing states these are restricted stock units (RSUs), with each RSU representing a right to receive one share of common stock. Following the reported transaction, the director beneficially owned 74,766 shares, held directly.
LifeStance Health Group (LFST) filed a Form 3 reporting the initial beneficial ownership of a director as of 08/20/2025. The filing states that no securities are beneficially owned. It was submitted by one reporting person and includes an Exhibit 24 Power of Attorney. This is an administrative disclosure required under Section 16 and does not reflect a transaction.
LifeStance Health Group insider report: Ann Varanakis, Chief People Officer and director, had restricted stock units vest on 08/26/2025. The issuer withheld 5,233 shares to satisfy tax withholding at $5.39 per share; this withholding is a net settlement and not an open-market sale. After the transaction, Ms. Varanakis beneficially owns 369,335 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and indicates the filing was made by one reporting person.
LifeStance Health Group reported a change in its board of directors. On August 19, 2025, William Miller resigned from the board and all its committees, effective immediately, and the company states his resignation was not due to any disagreement with the company. On August 20, 2025, the board appointed Sarah Personette as a new director.
In connection with her appointment, and under the company’s 2021 Equity Incentive Plan, Ms. Personette received an initial grant of 74,766 restricted stock units. These RSUs will vest based on time and performance conditions, subject to her continued service on the board.
Silversmith Partners reported an insider sale of common stock in LifeStance Health Group, Inc. (LFST). On 08/18/2025 the Silversmith Entities disposed of 3,592,357 shares at a price of $5.07 per share. After that transaction the reporting parties beneficially owned 14,324,197 shares on an indirect basis. The filing breaks down the indirect holdings: Silversmith Capital Partners I-A, L.P. holds 9,855,844 shares, Silversmith Capital Partners I-B, L.P. holds 3,565,133 shares, and Silversmith Capital Partners I-C, L.P. holds 903,220 shares. The report includes standard disclaimers that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and notes a stockholders agreement that may create a Section 13(d) "group" with other large holders. The form is signed by Jeffrey R. Crisan on 08/20/2025.
Darren M. Black, a director and 10% owner affiliate, reported a sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) on 08/18/2025 at a price of $5.07 per share. The shares sold were held across multiple Summit-related funds as detailed in the filing. After the transaction, the reporting parties continue to beneficially own a total of 33,524,715 shares held indirectly through Summit entities. The filing clarifies the ownership chain: Mr. Black is a Managing Director and Member of Summit Master Company, LLC, which through a series of partnerships and management relationships holds voting and dispositive authority over the reported shares.
Insider sale by Summit Partners entities: On 08/18/2025 multiple Summit-related entities reported an aggregate sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) at a price of $5.07 per share. After the reported transactions, the entities collectively beneficially own 33,524,715 shares held across five Summit funds and entities. The filings identify Summit Partners, L.P. as the manager with voting and dispositive authority exercised by a four-person investment committee. The report was signed and filed on 08/20/2025 by authorized representatives of the Summit entities.